Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to -$36.2 million.

  • Gossamer Bio's Cash from Operations fell 1290.54% to -$36.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.4 million, marking a year-over-year decrease of 1112841.96%. This contributed to the annual value of -$3.5 million for FY2024, which is 9782.1% up from last year.
  • Gossamer Bio's Cash from Operations amounted to -$36.2 million in Q3 2025, which was down 1290.54% from -$47.1 million recorded in Q2 2025.
  • Over the past 5 years, Gossamer Bio's Cash from Operations peaked at $116.3 million during Q2 2024, and registered a low of -$53.5 million during Q1 2022.
  • Moreover, its 4-year median value for Cash from Operations was -$38.3 million (2023), whereas its average is -$31.5 million.
  • As far as peak fluctuations go, Gossamer Bio's Cash from Operations skyrocketed by 40416.98% in 2024, and later plummeted by 14044.85% in 2025.
  • Quarter analysis of 4 years shows Gossamer Bio's Cash from Operations stood at -$47.7 million in 2022, then increased by 29.97% to -$33.4 million in 2023, then fell by 6.15% to -$35.5 million in 2024, then decreased by 1.93% to -$36.2 million in 2025.
  • Its Cash from Operations stands at -$36.2 million for Q3 2025, versus -$47.1 million for Q2 2025 and -$39.7 million for Q1 2025.